Results 31 to 40 of about 11,256 (207)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Frontiers in Pharmacology, 2023
Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair.
Ruihong Dong, Ruihong Dong, Ting Ding, Ting Ding, Zhengyu Li, Zhengyu Li   +5 more
doaj   +1 more source

PARP inhibitor resistance: the underlying mechanisms and clinical implications

Molecular Cancer, 2020
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi targeting poly (ADP-ribose) polymerase (PARP) have been approved for ovarian
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang   +5 more
doaj   +1 more source

Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions

, 2023
Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a new standard of care in the upfront treatment of advanced epithelial ovarian cancer to the point that the vast majority of patients now receive a PARPi, alone or in combination with the anti ...
Giuseppe Caruso, Nicoletta Colombo, Gabriella Parma, Francesco Multinu, Innocenza Palaia, Federica Tomao, Mariateresa Lapresa, Giovanni Aletti, Aletti G., Caruso G., Lapresa M., Tomao F., Multinu F., Palaia I., Colombo N., Parma G.   +15 more
core   +1 more source

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway

Cell Transplantation, 2023
Ovarian cancer (OC), particularly high-grade serous cancer (HGSC), is the leading cause of mortality among gynecological cancers owing to the treatment difficulty and high recurrence probability.
Qi Cao, Lanyang Li, Yuqing Zhao, Chen Wang, Yanghua Shi, Xiang Tao, Chunhui Cai, Xin-Xin Han   +7 more
doaj   +1 more source

The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing

Journal of Experimental & Clinical Cancer Research, 2021
Epithelial ovarian cancer (EOC) harbors distinct genetic features such as homologous recombination repair (HRR) deficiency, and therefore may respond to poly ADP-ribose polymerase inhibitors (PARPi).
Mengyu Tao, Xia Wu
doaj   +1 more source

Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models [PDF]

, 2018
Background Radiation injury can be indistinguishable from recurrent tumor on standard imaging. Current protocols for this differential diagnosis require one or more follow-up imaging studies, long dynamic acquisitions, or complex image post-processing ...
Garbow, Joel R., Thomas Reiner, Jannetti, Stephen A., Wolfgang A. Weber, Carney, Brandon, Patrick L. Donabedian, Brandon Carney, Engelbach, John A., Young, Robert J., Joel R. Garbow, Reiner, Thomas, John A. Engelbach, Robert J. Young, Susanne Kossatz, Stephen A. Jannetti, Weber, Wolfgang A., Donabedian, Patrick L., Kossatz, Susanne   +17 more
core   +2 more sources

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Journal for ImmunoTherapy of Cancer, 2023
Background Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer.
Changli Qian, Gordon J Freeman, Tao Jiang, Ursula Matulonis, Ziying Lin, Hye-Jung Kim, Anniina Färkkilä, Hua Yu, Xin Cheng, Panagiotis A Konstantinopoulos, Antons Martincuks, Joyce F Liu, Qiwei Wang, Liya Ding, Michael J Kearns, Shaozhen Xie, Inga-Maria Launonen, Thomas M Roberts, Jean J Zhao   +18 more
doaj   +1 more source

Néoplasies myéloïdes post-traitement par inhibiteurs de poly (ADP-ribose) polymérase (PARPi)

, 2021
Introduction : les inhibiteurs de poly (ADP-ribose) polymérase (PARPi) ont montré des résultats prometteurs dans différents cancers. Cependant, un risque de néoplasie myéloïde secondaire (NM-t) y serait associé.
Marmouset, Vincent
core   +1 more source

The role of PARP inhibitor combination therapy in ovarian cancer

Therapeutic Advances in Medical Oncology, 2023
The use of PARP inhibitors (PARPi) has transformed the care of advanced high-grade serous/endometrioid ovarian cancer. PARPi are now available to patients in both the first-line and recurrent platinum-sensitive disease settings; therefore, most patients ...
Helen Hockings, Rowan E. Miller
doaj   +1 more source

PARPi potentiates with current conventional therapy in MLL leukemia [PDF]

Cell Cycle, 2017
Acute myeloid leukemias driven by MLL fusion proteins are commonly associated with poor prognosis and refractory treatment. Here, we provide evidence that olaparib can potentiate sensitivity of MLL leukemia cells to conventional chemotherapy and DNMT inhibitors offering new potential therapeutic strategies for MLL rearranged leukemias Using the primary
Zhao, Lu, So, Chi Wai Eric
openaire   +3 more sources